Follow
Bryce Demoret
Bryce Demoret
Research Assistant
Verified email at osu.edu
Title
Cited by
Cited by
Year
Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma
KLJ Bill, ND Seligson, JL Hays, A Awasthi, B Demoret, CW Stets, ...
The oncologist 24 (7), 989-996, 2019
322019
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma
ND Seligson, CW Stets, BW Demoret, A Awasthi, N Grosenbacher, ...
Oncotarget 10 (55), 5671, 2019
122019
Prospective evaluation of the concordance of commercial circulating tumor DNA alterations with tumor-based sequencing across multiple soft tissue sarcoma subtypes
B Demoret, J Gregg, DA Liebner, G Tinoco, S Lenobel, JL Chen
Cancers 11 (12), 1829, 2019
112019
MDM2-dependent rewiring of metabolomic and lipidomic profiles in dedifferentiated liposarcoma models
A Patt, B Demoret, C Stets, KL Bill, P Smith, A Vijay, A Patterson, J Hays, ...
Cancers 12 (8), 2157, 2020
102020
Loss of TXNIP enhances peritoneal metastasis and can be abrogated by dual TORC1/2 inhibition
D Spaeth-Cook, M Burch, R Belton, B Demoret, N Grosenbacher, J David, ...
Oncotarget 9 (86), 35676, 2018
42018
Identification of histone deacetylase 2 (HDAC2) as a novel target for MDM2 directed therapies in dedifferentiated liposarcoma.
CW Stets, B Demoret, N Grosenbacher, JL Hays, JL Chen
Journal of Clinical Oncology 36 (15_suppl), 11583-11583, 2018
22018
Exploring ceramide metabolism as a potential target in dedifferentiated liposarcoma.
B Demoret, A Patt, CW Stets, M Hoang, JL Hays, E Mathe, JL Chen
Journal of Clinical Oncology 37 (15_suppl), e22558-e22558, 2019
2019
DEGREE OF MDM2 AMPLIFICATION AFFECTS CLINICAL OUTCOMES IN DEDIFFERENTIATED LIPOSARCOMA.
ND Seligson, KLJ Bill, JL Hays, B Demoret, CW Stets, M Duggan, ...
CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S38-S38, 2019
2019
Pilot study evaluating the concordance of circulating tumor DNA alterations with tumor-based sequencing in soft tissue sarcoma
B Demoret, S Millis, G Tinoco, D Lieber, JL Chen
Connective Tissue Oncology Society, 2018
2018
Identifying predictive markers and novel combinations for TORC1/2 inhibition in ovarian and endometrial cancer
N Grosenbacher, S Crafton, J David, C Stets, B Demoret, J Chen, J Hays
EUROPEAN JOURNAL OF CANCER 103, E132-E132, 2018
2018
Modulation of MDM2 alters the metabolomic programming of dedifferentiated liposarcoma and its sensitivity to cholesterol inhibition
B Demoret, A Patt, J Hays, E Mathé, JL Chen
Cancer Research 78 (13_Supplement), 3529-3529, 2018
2018
Genomic amplification of CDK4 in dedifferentiated liposarcomas as a predictive biomarker for microtubule disrupting agents.
B Demoret, A Rogers, ND Seligson, EA Kautto, JL Hays, JL Chen
Journal of Clinical Oncology 36 (15_suppl), 11581-11581, 2018
2018
The system can't perform the operation now. Try again later.
Articles 1–12